
Welcome to this month’s ADVOCATE BRIEF
Forward this to someone on your team who needs it.

Thank you to every veteran and military family.
Today is Veterans Day, and I want to start by thanking every veteran and military family who reads this Brief for your service. You are patients too, and many of you bring that same commitment to advocacy for the people next to you in the waiting room.
October moved health policy into the courtroom. Hospitals sued to stop a 340B rebate pilot. PhRMA sued to stop a Medicare pricing model. More than two dozen states won a ruling on who counts as too sick to meet the new Medicaid work rules. At least five Medicare Advantage insurers sued over their own quality grades. Then on November 3, voters gave Democrats both chambers of Congress, and the people who write the next round of rules changed.
The numbers behind the lawsuits land on patients. ICER and West Health put the median net launch price of new drugs at $257,000 in 2025. KFF projects standalone Part D premiums rising 50 percent in 2027 for seniors who keep their current plans. The Commonwealth Fund found 46 percent of working-age adults inadequately insured in 2026, before the Medicaid changes take effect.
I have watched enough of these fights to know that a ruling settles the law and leaves the paperwork to the patient. Every case this month came back to the two questions a patient actually asks, which are whether the drug arrives and what it costs.
Four storylines ran through October, and they share one lesson. The organizations that bring patient evidence to the docket, the hearing room and the benefit design table before January will shape what their communities can reach in 2027.

The rules patients live under in 2027 now run through the courts.
POLICY PULSE: POLITICAL
October sent 340B, Medicare drug pricing and Medicaid work rules to court, and November 3 changed who holds the pen. Advocates now have a new Congress to brief and a busy docket to watch.
The American Hospital Association sued the administration a second time to halt HRSA’s 340B Rebate Model Pilot. Starting January 1, 2027, rebates replace upfront discounts on CMS selected drugs, so hospitals and clinics pay first and wait for the rebate. The program keeps growing. HHS’s Office of the Assistant Secretary for Planning and Evaluation reports that 340B drug sales “have increased from $12 billion in 2015 to $81 billion in 2024.” STAT reports the expanded pilot “would target 25 of the costliest, most widely used drugs covered under Medicare. The original plan included 10 drugs.” HRSA received more than 2,400 comments before moving ahead. Ask your hospital and health center partners one question this month: what happens to patient services if the rebate check arrives late?
PhRMA sued in federal court in Washington, D.C., arguing the GLOBE most favored nation pricing pilot “exceeds Medicare’s statutory authority,” STAT reported. On Medicare negotiation itself, Health Affairs describes an “unbroken record” for the government, and industry now shifts to statutory and administrative law challenges. CMS proposed permanent rules for the Medicare Drug Price Negotiation Program on June 12 (CMS-4215-P); the comment period closed August 17. My read: the final rule becomes the next target.
A federal judge in Massachusetts vacated CMS’s definition of who counts as “medically frail” under the new Medicaid work requirements, siding with 25 states and the District of Columbia. Judge Richard Stearns found the definition more limited than Congress intended. He upheld the 12-month limit on medical claims and visit data and the limits on self-attestation, and gave states six months before enforcing frailty determinations. CMS could appeal. Starting in 2027, expansion adults must log at least 80 hours a month of work, volunteering or school. The Center on Budget and Policy Priorities estimates the work requirements “will put 9.9 million to 14.9 million people at risk of losing Medicaid coverage in 2034.” Help members with serious conditions gather 12 months of claims and visit records now.
On November 3, voters gave Democrats control of both chambers of Congress, starting January 3, 2027. Health Affairs reports that a House Democratic working group’s first-100-hours list includes blocking the 340B pilot and the WISeR prior authorization model, stabilizing Medicare drug plan premiums, and reversing H.R. 1’s Medicaid cuts. The 60-vote Senate threshold and the presidential veto still limit what becomes law. Oversight hearings run on patient evidence, so start building your file now.
Courts and Congress now decide the rules patients live under in 2027. A member story handed to a committee investigator, or a comment backed by intake data, gives an advocacy organization a real seat in that process.

Prices start high and climb at every renewal.
COST OF CARE: ECONOMIC
The cost story in October came down to timing. Prices start high at launch, premiums jump at renewal, and patients feel both before any relief arrives.
ICER and West Health reported on October 20 that “the median net launch price of drugs rose sharply, by 35%, from $190,000 in 2022 to $257,000 in 2025 (adjusted for inflation).” Access lags too. In the first year after approval, “only one-third of outpatient prescriptions ultimately filled within 30 days of attempting to fill them.” ICER CEO Sarah Emond put it plainly: “Overpayment for drugs beyond their value to patients is contributing to decreased patient access.” Ask every company you partner with for its first-year access numbers alongside its price.
KFF projects average standalone Part D premiums rising 50 percent, from $34 to $51 a month in 2027, for seniors who keep their current plans. Three-fourths of enrollees without financial help, 10.4 million seniors, pay more if they stay put, and no zero-premium standalone drug plans exist for 2027. The standard deductible rises from $615 to $700. Open enrollment runs until December 7, so put a plan comparison checklist in your next member email.
Coverage costs more at every door. KFF found total family premiums now average $28,303 a year, and workers pay $7,471 of that on average, up 9 percent. The administration “cut health subsidies for 189,000 people” it flagged as deceased or duplicate ACA enrollees. The Commonwealth Fund found the uninsured rate for working-age adults increased from 8.9 percent in 2024 to 11.2 percent in 2026, and half of working-age adults went without needed care because of the cost. Tell your community to open every letter from Medicaid, the marketplace and their plan, because a missed deadline can end coverage.
The Labor Department finalized a rule requiring pharmacy benefit managers to disclose rebates, spread payments and other compensation to large self-insured employers at contracting, at renewal and every six months, starting July 2027. Employers can audit those disclosures once a year, and regulators expect the rule to lower drug costs for employers and workers by $22 billion over a decade. The PBM lobby calls it redundant. The AMA found the four largest PBMs held 75 percent of the national market in 2024, up from 70 percent in 2022: OptumRx and Express Scripts at 23 percent each, CVS Caremark at 18 percent and Prime Therapeutics at 11 percent. Patient organizations with employer partners can ask them to use the new audit right and share what they learn.
CVS Health sued CMS to vacate its 2027 Medicare Advantage star ratings, at least the fifth insurer to sue after Alignment, Healthfirst, SCAN and Centene. CVS says its share of members in plans rated four stars or higher fell from 84 percent to 67 percent, and it claims a $2 billion hit to 2028 payments. STAT reports that getting at least four stars “triggers bonuses, which total $13 billion across the industry annually.” Star ratings exist to help patients choose a plan, so members deserve to know which quality measures insurers want thrown out.
Cost now reaches patients at launch, at renewal and at the pharmacy counter. Advocacy organizations see those costs first, which gives them the evidence employers, plans and policymakers keep asking for.

Save the patient a seat before the decisions lock.
COMMUNITY LENS: SOCIOCULTURAL
Patients told the system what they need this month, in research rooms, at the pharmacy counter and in advisory committee seats. The organizations that listen early earn the trust.
ASCO published a practical guide on working with patient advocates in research. Laurie Hutcheson of the Lobular Breast Cancer Alliance laid out the basics: include patient advocates from the start, bring more than one, compensate them as you would other team members, and define the role with the advocate’s input. As she puts it: “The goal is to ensure that patient voices are heard and that resultant decisions about patient care are fully patient-centered.” Industry has work to do here. In ELAVAY 2026, access to company leadership is the lowest-scoring relationship attribute among all respondents, at 5.07 on a 7-point scale. It ranks last in every 2026 cut (all-respondent 5.07; mental health 5.73; oncology 5.30). Send ASCO’s four rules to every sponsor that asks you to help recruit.
This story discusses suicide. If you or someone you know is in crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline. KFF Health News reported the story of Kenney Blewett, a Texas man living with COPD. On June 2, his pulmonologist wrote him a prescription for a new medication. Two days later, Walgreens emailed that the drug was delayed “due to an insurance issue that we’re working to resolve.” He died by suicide on June 7. His wife, Cindy, still has questions about who was responsible for the delay. “I wish we had the chance to find out,” she said of the drug. KFF Health News quoted me in that story: “It’s just gotten completely out of hand.” Patients need real help facing these hurdles. A JAMA study shows the scale: “Across the study window, 32 percent of initial attempts for single-source brand-name drugs were rejected for formulary-related reasons: 14.8 percent as formulary exclusions and 17.2 percent for prior authorization or step therapy. Among those rejected attempts, 48.4 percent were not followed by a fill of the prescribed drug or another in the same therapeutic class within 90 days.” Map the path a patient takes when a pharmacy and a plan point at each other, name who to call and in what order, and publish it.
Advocates can move these rules. National Psoriasis Foundation President and CEO Leah Howard described one insurer’s 2026 policy that required patients to try “14 other therapies, over 42 months” before reaching the psoriasis treatment their clinician wanted, Bio.News reported. The foundation and its partner groups in Pennsylvania got the insurer to cut the list to “five alternative therapies and 15 months.” Bring that level of detail to every plan in your state that stacks step therapy.
A USC Schaeffer Institute study of 234 FDA drug advisory committee meetings from 2013 to 2022 found that 38.0 percent included a patient or consumer representative from an organization that received pharmaceutical funding that same year, RAPS reported. In 10.7 percent of meetings, the organization had received funding from the sponsor of the product under review. The authors want FDA to publish conflict waivers and revise its disclosure form. Patient advocacy organizations can lead here by publishing their funding sources and their rules for who speaks on their behalf.
Trust grows when patients hold a real seat before decisions lock, and it erodes when that seat comes with ties nobody discloses. ELAVAY measures that trust every year.

Faster answers help. The criteria behind them decide who gets care.
Yes, that Arnold Schwarzenegger.
He has a newsletter on beehiiv. So do Codie Sanchez, Jay Shetty, David Begnaud, Colin & Samir, and Joanna Stern.
They could publish just about anywhere. They chose beehiiv to build a direct connection with the people who want to hear from them most. And you can do the same, whether you’re world-famous or just at the start of your plan for world domination.
TECH TRENDS: TECHNOLOGY
Amazon, Axon Enterprise, Google, Meta and Oracle “pledged to implement electronic prior authorizations in their self-funded health plans,” Healthcare Dive reported. “They join nearly 60 health plans that signed a voluntary pledge last year.” The pledge stays voluntary, so ask the employers in your community whether they signed and what changed for their workers.
Humana now connects to more than 180,000 providers on athenahealth’s network for electronic prior authorization. In September, more than 6,000 providers processed nearly 35,000 electronic prior authorizations with Humana, and over 70 percent finished without additional information from staff, according to athenahealth data reported by Fierce Healthcare.
Aetna expanded bundled prior authorizations to all cancer treatments, so an oncologist files one request covering chemotherapy, immunotherapy, radiation and related imaging. The program runs for Medicaid members in eight states today, with Medicare and commercial members planned for the first half of 2027. ASCO wants care that follows NCCN guidelines exempted from prior authorization and a status tracker that patients and providers can both check. Cancer organizations can ask every plan in their region for the same.
Patients want a human in the loop. In a Pew Research Center survey of 3,488 U.S. adults, 46 percent said AI should not decide insurance claims even with human review, and 58 percent had little or no confidence that payers will use AI in patients’ best interest. The AMA released a clinical AI liability framework that ties responsibility to each party’s ability to prevent harm, and its president said patients “must have meaningful avenues for recourse when clinical AI causes harm.”
Automation speeds approvals and denials alike. Advocacy organizations that review the criteria while they sit in draft will shape who gets the faster yes.
THE BOTTOM LINE
October 2026 proved that patient access now gets argued in court before it reaches the clinic. Hospitals, drugmakers, insurers and states all sued over the rules, and on November 3 voters changed who writes the next ones. Launch prices, Part D premiums and employer premiums all climbed while the cases moved.
Pharma and biotech teams that bring advocate insight into 2027 planning now will lead the next two quarters. Patient advocacy organizations that hand member evidence to the new Congress, walk members through Part D open enrollment before December 7, and prepare members for the Medicaid work rules will decide what their communities can reach next year.
Take the Advocacy Influence Diagnostic at aid.elavay.com to evaluate your advocacy function’s influence and get a real understanding of its impact within your organization.
Find every source cited in this brief, and the other articles our CEO, Matt Toresco, found valuable last month, at intelligence.archo.io.
For ELAVAY Intelligence briefings and Archō syndicated research on how patient advocacy organizations evaluate pharma and biotech companies, email [email protected].
For advocacy strategy consulting or advocacy function training to maximize your team’s engagement and influence, reach Matt directly at [email protected].
Connect with the advocacy community and find patient and advocacy resources at advocatebridge.org.
ELAVAY FIELDING BEGINS THIS MONTH
Each year, we ask 20,000 patient advocacy organizations, professional societies, and community-based organizations to participate in ELAVAY's fielding to ensure we capture the full spectrum of patient advocacy organizations in the industry.
ELAVAY fielding begins in November 2026. Make sure your organization is counted. Learn more at ELAVAY.com, or book time with Matt Toresco, Editor in Chief, ELAVAY.
SOURCE ARTICLES BY SECTION
Policy Pulse
Hospitals sue, again, to halt Trump administration’s 340B rebate pilot (STAT): https://www.statnews.com/2026/10/09/hospitals-sue-to-halt-340b-rebate-pilot-trump/
Notice regarding 340B Rebate Model Pilot Program (Federal Register): https://www.federalregister.gov/documents/2026/08/03/2026-15633/notice-regarding-340b-rebate-model-pilot-program
PhRMA sues over Trump policy mandating lower drug prices in Medicare (STAT): https://www.statnews.com/2026/10/07/phrma-sues-over-drug-pricing-model-globe/
More Industry Losses In Medicare Drug Prices Litigation (Health Affairs): https://www.healthaffairs.org/content/forefront/more-industry-losses-medicare-drug-prices-litigation
Medicare Drug Price Negotiation Program guidance and CMS-4215-P (CMS): https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/guidance-policy-documents
Judge strikes down CMS ‘medical frailty’ policy for Medicaid work requirements (Healthcare Dive): https://www.healthcaredive.com/news/judge-strikes-down-cms-medical-frailty-policy-medicaid-work-requirements/873284/
What The 2026 Midterm Elections Mean For Health Policy (Health Affairs): https://www.healthaffairs.org/content/forefront/2026-midterm-elections-mean-health-policy
Mission vs. Margin: Misaligned Incentives in the 340B Drug Pricing Program (HHS ASPE): https://aspe.hhs.gov/sites/default/files/documents/6ec5c02373a85f8bdfd21eae48b72417/2026-10-06-%20ASPE%20340B%20Brief.pdf
Medicaid Work Requirements Will Take Away Coverage From Millions (Center on Budget and Policy Priorities): https://www.cbpp.org/research/health/medicaid-work-requirements-will-take-away-coverage-from-millions-state-and
Cost of Care
ICER, West Health Release New Report Indicating that Median Prices of Newly Launched Drugs Continue to Exceed $250,000 (West Health): https://westhealth.org/news/icer-west-health-release-new-report-indicating-that-median-prices-of-newly-launched-drugs-continue-to-exceed-250000/
Medicare Part D premiums are spiking 50% on average next year, KFF finds (Healthcare Dive): https://www.healthcaredive.com/news/medicare-part-d-premiums-skyrocket-2027-kff/873421/
2026 Employer Health Benefits Survey news release (KFF): https://www.kff.org/private-insurance/workers-now-pay-7471-on-average-annually-for-family-health-coverage-up-9-or-621-from-2025-benchmark-employer-health-benefits-survey-finds/
Trump administration boots 189,000 deceased, duplicate enrollees off ACA subsidies (Healthcare Dive): https://www.healthcaredive.com/news/trump-administration-boots-189000-deceased-duplicate-enrollees-off-aca-su/833037/
The State of Health Insurance Coverage in 2026 (Commonwealth Fund): https://www.commonwealthfund.org/publications/surveys/2026/oct/state-health-insurance-coverage-2026-biennial-survey
Labor Department finalizes sweeping PBM disclosure rule (Healthcare Dive): https://www.healthcaredive.com/news/pbm-transparency-final-rule-labor-department-employer/873089/
CVS sues to prevent $2B Medicare Advantage star ratings hit (Healthcare Dive): https://www.healthcaredive.com/news/cvs-aetna-lawsuit-medicare-advantage-star-ratings-2027-cms-2-billion/873000/
Medicare Advantage star ratings trigger new bonuses, and uncertainty (STAT): https://www.statnews.com/2026/10/09/medicare-advantage-insurers-star-ratings-2027-humana-alignment/
AMA analysis: PBM market concentration continues to rise (AMA): https://www.ama-assn.org/press-center/ama-press-releases/ama-analysis-pbm-market-concentration-continues-rise
Community Lens
Patient Advocacy 101: Working With Patient Advocates in a Research Setting (ASCO Connection): https://connection.asco.org/do/patient-advocacy-101-working-patient-advocates-research-setting
Patient Dies by Suicide After ‘Insurance Issue’ Delayed Medicine for Lung Disease Flare-Ups (KFF Health News): https://kffhealthnews.org/health-industry/insurance-issue-delayed-copd-prescription-breathing-problems-suicide-texas/
Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States (JAMA): https://jamanetwork.com/journals/jama/fullarticle/2851461
Study: Patient, consumer reps at FDA adcomms increasingly hold ties to pharma-backed advocacy groups (RAPS): https://www.raps.org/resource/study-patient-consumer-reps-at-fda-adcomms-increasingly-hold-ties-to-pharma-backed-advocacy-groups.html
PACE: Pushing past pain to achieve access for the 21st Century (Bio.News): https://bio.news/latest-news/pace-pushing-past-the-pain-to-achieve-access-for-the-21st-century/
Tech Trends
Five major companies pledge faster, electronic prior authorizations (Healthcare Dive): https://www.healthcaredive.com/news/five-major-companies-pledge-faster-electronic-prior-authorizations/833848/
Humana, athenahealth collaborate on expanded electronic prior authorizations nationwide (Fierce Healthcare): https://www.fiercehealthcare.com/payers/humana-athenahealth-collaborate-expanded-electronic-prior-authorizations-nationwide
Aetna bundles cancer treatment prior authorizations following industrywide scrutiny (Healthcare Brew): https://www.healthcare-brew.com/stories/aetna-bundles-cancer-treatment-prior-authorizations-scrutiny
Patients want a human in the loop for AI healthcare tools (Healthcare Dive): https://www.healthcaredive.com/news/patients-want-human-in-loop-ai-healthcare-tools/873704/
Who’s responsible when clinical AI goes wrong? AMA weighs in (Fierce Healthcare): https://www.fiercehealthcare.com/ai-and-machine-learning/whos-responsible-clinical-ai-ama-has-some-thoughts
ELAVAY
ELAVAY: https://elavay.com
ALL SOURCES CAN ALSO BE FOUND AT https://intelligence.archo.io
EMPWRD Patient Foundation builds tools for patients and advocacy organizations so patients get the care they deserve. You can see more about us at empwrdpatientfoundation.org


